REFERENCE FILE
Dulaglutide
Read the record, then work through the questions.
Reference details
Status as of
- Regulatory category
- Approved product
- Evidence category
- Randomized evidence
- Mechanism
- GLP-1 receptor agonist fusion protein.
- Evidence
- Randomized studies.
- Limitations
- No weight-management indication.
- Safety
- Not recommended for severe gastroparesis.
- Formulation and route
- Subcutaneous injection.
- Approval scope
- Trulicity: specified type 2 diabetes populations.
A SECOND LOOK
A question to carry into the reading
Separate the doorway from the people who walked through it when reading about dulaglutide. Draw a line between the entry rules and the description of actual participants. Place each statement on the appropriate side, rather than treating permission to enter as evidence that someone did enter. If a report supplies a participant flow diagram, use it to follow the stages from consideration to inclusion in an analysis. Do not fill an unexplained transition with a guessed reason. Your finished sketch should show which group a result describes and which earlier group would need additional information before being treated as equivalent.
Questions to keep beside the page
- Does this sentence describe eligibility rules or people who actually participated?
- Which stage of the participant flow supplies the reported result?
- What information would explain a difference between the eligible and analyzed groups?
Sources for this file
- TRULICITYNLM · Checked
FROM THE REFERENCE DESK